Antimicrobial Resistance: A Worldwide Crisis

The rapid emergence of resistant bacteria is occurring worldwide, endangering the efficacy of antibiotics. This crisis has been attributed to the misuse and overuse of antibiotics. The CDC and other organizations and experts recommend improving microbial identification and optimizing therapeutic regimens, among other actions, to combat this current crisis. As often as 50% of the time, antibiotics are being prescribed either unnecessarily or incorrectly. These findings highlight the need for quick and accurate pathogen identification, as well as the use of genetic markers for antibiotic resistance detection. Our expert therapeutic guidance will help preserve the effectiveness of antibiotics for many generations to come. This is our commitment in providing the best individualized Antibiotic Stewarship program to you and your patients.

What Sets Us Apart

ATA provides the most comprehensive molecular PCR analysis in the country. Our patent-pending, proprietary process delivers true antimicrobial stewardship customized to each patient. A live team of clinical pharmacists are available 24/7, and they use this proprietary process to interpret reports and give personalized treatment recommendations for your patients.

The rise in antibiotic resistance dictates the necessity of a new approach to prescribing antimicrobial therapies. The logic behind old schools of thought, where one pathogen is responsible for the infection and one antimicrobial can “cure” it, is outdated. Our patent-pending, clinical process and utility method takes the guesswork out of prescribing antibiotics. The ATAREPORT™ report customizes therapeutic guidance with your patient population in mind.

Quantitative PCR data differentiates pathogenic organisms from noninfectious organisms, which is vital for providing true antibiotic stewardship for targeted patient therapy. To protect our precious supply of available antibiotics, diagnostic tools must yield better than simply “positive” or “negative” results. Therefore, at ATA we only work with the top labs in the country that have met our standard of excellence.

Our mission at ATA is to take empirical guessing out of prescribing antibiotics for infectious disease.

Therapeutic guidance paired with superior molecular diagnostic tools will optimize patient outcomes, reduce hospital admissions, and significantly improve antibiotic stewardship. 

Our Competitors

• Our competitors rely on culture and sensitivity pharmacy databases for their prescribing algorithms. This empirical analysis is, at best, an educated guess on which antibiotic might work, and this analysis is not compatible with multi-pathogen and multi-resistant gene detections by PCR technology. 
• Some competitors base their pharmacy guidance on qualitative PCR data. This promotes OVERUSE of antibiotics and false antibiotic stewardship. 
• Our competitors focus on finding one drug to treat one organism. It is very important to comprehensively treat the entire infection for all gram-positive, gram-negative, and anaerobic bacteria found to be pathogenic. 
• At ATA, we add in valuable clinical assessments from our clinics to eliminate inappropriate medication classes from our report. This allows us to make therapy recommendations, based on multiple clinical markers, with the highest statistical chance of success for that specific patient, because we know that not all patients are the same.  

Think about it this way...

If you do not know the pathogen because of the lack of quantitative measures,

If you do not know the resistance because of the poor grouping of enzymes,

If you do not know which R gene is clinically relevant to which organisms,

Then your pharmacy guidance is just simply an empiric guess.

Experience the ATA Difference

Use our 12-step method to get it right the first time.

RX Hotline: 855-742-7635 | Business Lines: 479-531-0366